Dr. Mody’s primary research interest includes use of precision oncology approach for designing innovative clinical trials for refractory childhood cancers. Dr. Mody is leading a clinical trial investigating the role of next generation sequencing (NGS) in precision oncology for developing novel biomarkers and therapeutic targets against refractory childhood cancers. This effort is being carried out in collaboration with the laboratory of Dr. Arul Chinnaiyan in the Michigan Center of Translational Pathology (MCTP).
Dr. Mody’s other research interest includes development of early phase clinical trials against refractory childhood cancers. He is the Principal Investigator of international Phase-II, randomized trial of Chimeric 14.18 or Temsirolimus in combination with Irinotecan/ Temozolomide through Children’s Oncology Group (COG). He is a member of the High Risk Neurobalstoma Committee of COG, institutional performance review committee for COG Phase-I consortium and is the Principle Investigator of the Children's Oncology Group, Phase-I, Phase II-III Consortium studies at C.S. Mott Children's Hospital.
